Close Menu
    What's Hot

    American Businessman Mark Eric Williams Vindicated in Six-Year, US$150 Million-Plus Litigation Brought by Kuwaiti State Entities

    November 20, 2026

    ADFW 2026 Unveils Largest-Ever Partner-Driven Programme, Headlined by L’IMAD

    November 20, 2026

    Air Arabia Egypt launches Cairo to Al Ain flights soon

    November 20, 2026
    • Home
    • Contact Us
    Bahrain BulletinBahrain Bulletin
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • Sports
    • Technology
    • Travel
    Bahrain BulletinBahrain Bulletin
    Home » Wegovy sales weaken in US pushing Novo Nordisk to cut yearly guidance
    Featured News

    Wegovy sales weaken in US pushing Novo Nordisk to cut yearly guidance

    July 30, 2025
    Facebook WhatsApp Twitter Pinterest LinkedIn Telegram Tumblr Email Reddit VKontakte

    Shares of Danish pharmaceutical company Novo Nordisk fell sharply by 20% on Tuesday after the company cut its full-year sales and profit outlook and named a new chief executive officer. The market reaction came amid ongoing challenges in the U.S. market for the company’s widely used obesity and diabetes drugs.

    Novo Nordisk now expects full-year 2025 sales growth of 8% to 14%, down from its previous projection of 13% to 21%. Operating profit growth is expected to range between 10% and 16%, also lower than the prior estimate of 16% to 24%. The company cited slower-than-anticipated sales of its weight-loss drug Wegovy and diabetes treatment Ozempic in the second half of the year as key drivers of the revised outlook.

    The company also announced that Maziar Mike Doustdar will take over as president and CEO, effective August 7. A Novo Nordisk veteran since 1992, Doustdar most recently served as executive vice president for international operations. His appointment follows the unexpected departure of Lars Fruergaard Jørgensen, whose removal was announced in May after a prolonged decline in the company’s stock performance.

    Wegovy and Ozempic sales pressure second-half performance

    Despite reporting a 40% increase in second-quarter operating profit and an 18% rise in sales year-on-year, Novo Nordisk warned of slower momentum for the remainder of the year. It noted that compounded GLP-1 drugs continue to impact demand for Wegovy in the U.S., even after the expiration of a temporary exemption granted by the U.S. Food and Drug Administration (FDA) earlier in 2025.

    Competition in the weight-loss drug market has also intensified. Prescriptions for rival Eli Lilly’s weight-loss drug Zepbound surpassed those of Wegovy in March. In addition, Novo Nordisk has faced negative sentiment following disappointing clinical trial results for its next-generation obesity candidate, CagriSema.

    Stock price falls over 50 percent year-to-date

    The company is actively pursuing legal and regulatory strategies to combat the impact of unauthorized compounded drugs in the U.S. market. Executives have indicated that they expect availability of copycat drugs to decline in the second half of the year, but uncertainty remains regarding the pace of recovery in U.S. sales. Novo Nordisk’s stock has declined more than 50% over the past year.

    Tuesday’s selloff erased significant gains made during the prior year’s Ozempic-driven rally, which had briefly made Novo Nordisk the most valuable listed company in Europe. Analysts say investors will be watching closely for the company’s full second-quarter earnings report, scheduled for release on August 6, as well as updates on its product pipeline and regulatory developments. – By Eurowire News Desk.

    Related Posts

    Network International and AdalFi Partner to Unlock Data-Driven Lending Across the Middle East and Africa

    November 16, 2026

    Gulf Medical University Ranked 1st for International Student Ratio in QS Arab Region Rankings 2027

    October 22, 2026

    Dataroid Recognized in the Gartner® Market Guide for Product Analytics (2026)

    October 6, 2026

    Wibmo Fraud & Risk Management wins Chartis Disruptor Award for its Agentic Risk Intelligence Solution

    September 28, 2026

    VitrA Tiles Introduces “The Code” concept and the New Codes of Design at Cersaie Fair

    September 25, 2026

    115 Nationalities Since Inception, Gulf Medical University Welcomes the Global Cohort and Its First Veterinary Batch at White Coat Ceremony 2026

    September 23, 2026
    Latest News

    Air Arabia Egypt launches Cairo to Al Ain flights soon

    November 20, 2026

    Bilateral aviation connectivity between the Arab Republic of Egypt and the United Arab Emirates is expanding significantly heading into the final month of the year. Official commercial statements confirm that Air Arabia Egypt launches Cairo to Al Ain flights beginning

    Botswana reviews proposed 33% power tariff hike today

    November 19, 2026

    The state energy regulator has officially initiated a comprehensive public review process regarding a substantial electricity rate increase requested by the national utility provider. Confirming the scope of this critical regulatory review, Botswana opens consultations on proposed 33 percent power

    PM Modi meets Prince and Princess of Wales for climate talks

    November 19, 2026

    The economic and strategic relationship between New Delhi and London is accelerating as both governments move to modernize their historic bilateral frameworks. Official state updates confirm that PM Modi meets Prince and Princess of Wales to advance the comprehensive strategic

    Ebola adds 60 cases in a day as Congo deaths hit 5,568

    November 18, 2026

    – Ebola infections in the Democratic Republic of the Congo rose by 60 in a single day, as the death toll climbed to 5,568. The National Institute of Public Health said on Monday, November 16, that 11,376 cases have been

    © 2026 Bahrain Bulletin | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.